We are the first company in domestic to approach this product at the moment.

Sample is available on Mid-Oct, 2014.

Good service, your good business partner.

Other Drug Names: OCA, Intercept; DSP-1747; FXR agonists, Intercept; INT-747; farnesoid X
receptor agonists, Intercept; 6ECDCA; UPF-747; obeticholic acid： OCA, Intercept; DSP-1747; FXR agonists, Intercept; INT-747; farnesoid Xreceptor agonists, Intercept; 6ECDCA; UPF-747; obeticholic acid

Innovator: Intercept Pharmaceuticals Inc; Sumitomo Dainippon Pharma Co Ltd

Inactive Companies： Universita di Perugia

Sep, 2014, highest status: Phase 3 Clinical

Active Indication: Liver disease; Primary sclerosing cholangitis; Alcoholic hepatitis; Primary biliary
cirrhosis; Diarrhea; Portal hypertension; Non-alcoholic steatohepatitis

Inactive Indications:Jaundice;Non alcoholic fatty liver disease

Farnesoid X receptor agonist

Other Actions: Anti-inflammatory; Bile acid modulator

Technologies: Oral formulation; Small molecule therapeutic

route of synthetic: